Your Article Summary
See Latest ArticlesAnakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure
Joint, Bone, Spine, 04/23/09
Announ N et al. - The authors describe the case of a 71-year-old man with recurrent pseudogout attacks affecting multiple joints. He had end-stage renal failure that contra-indicated the use of non-steroidal anti-inflammatory drugs and was resistant to therapy with glucocorticoids. Based on the recent findings that interleukin (IL)-1-beta is involved in crystal-induced inflammation, the patient received anakinra, a specific IL-1 inhibitor, in order to treat an acute attack of pseudogout.
Related Articles
Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica
Clinical Interventions in Aging, 10/01/09
Relevance Score: 83%
Today in Gout and Hyperuricemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Taking the stress out of managing gout
Canadian Family Physician, 12/17/09
Clinical study of gout in North Kerala
Indian Journal of Rheumatology , 12/15/09
Treatment of chronic tophaceous gout with a free flap
Clinical Rheumatology, 12/14/09